10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024

$TXG
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $TXG alert in real time by email

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022

PLEASANTON, Calif., Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024.

Recent Highlights

  • Revenue was $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, representing 18% and 20% increases over the corresponding periods of 2022.
  • Increased cumulative instruments sold to 5,966 as of the end of 2023, comprising 5,180 Chromium instruments, 531 Visium instruments and 255 Xenium instruments.
  • Launched preorders for Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at single cell-scale resolution.
  • Unveiled and launched preorders for the first two products featuring Chromium GEM-X technology, the next generation of the company's leading single cell technology architecture, enabling higher performance at larger scale and lower cost.

"Our innovation engine has consistently delivered transformational technologies that have enabled our customers to expand the frontiers of science," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We're building on last year's extraordinary launch of Xenium with new, franchise-defining products in each of our three platforms that will take our portfolio to the next level. Our priority is to ensure our customers' success with these new products as we work together to deliver on the full promise and potential of single cell and spatial biology to advance human health."

Fourth Quarter 2023 Financial Results

Revenue was $184.0 million for the three months ended December 31, 2023, a 18% increase from $156.2 million for the three months ended December 31, 2022. This increase was primarily due to a higher volume of Spatial instruments and consumables sold.

Gross margin was 63% for the fourth quarter of 2023, as compared to 76% for the corresponding prior year period. The decrease in gross margin was primarily due to product mix with a higher mix of Spatial instruments sold.

Operating expenses were $171.0 million for the fourth quarter of 2023, a 20% increase from $142.5 million for the corresponding prior year period. The increase was primarily driven by $19.6 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year and impairment charges related to long-lived assets.

Operating loss was $55.2 million for the fourth quarter of 2023, as compared to an operating loss of $23.1 million for the corresponding prior year period. Operating loss also includes $38.9 million of stock-based compensation for the fourth quarter of 2023, as compared to $41.0 million for the fourth quarter of 2022.

Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the corresponding prior year period. This includes $19.6 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year.

Full Year 2023 Financial Results

Revenue was $618.7 million for the year ended December 31, 2023, a 20% increase from $516.4 million for 2022.

Gross margin was 66% for full year 2023, as compared to 77% for 2022. The decrease in gross margin was primarily due to product mix with a higher mix of Spatial instruments sold.

Operating expenses were $674.6 million for full year 2023, as compared to $564.0 million for 2022, an increase of 20%. The increase was primarily driven by $61.0 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year and higher personnel expenses including stock-based compensation expense.

Operating loss was $265.3 million for full year 2023, as compared to an operating loss of $167.9 million for 2022. This includes $167.0 million of stock-based compensation for full year 2023, as compared to $136.8 million for full year 2022.

Net loss was $255.1 million for full year 2023, as compared to a net loss of $166.0 million for 2022. This includes $61.0 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year.

Cash and cash equivalents and marketable securities were $388.7 million as of December 31, 2023.

2024 Financial Guidance 

10x Genomics expects full year 2024 revenue to be in the range of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the fourth quarter and full year 2023 financial results, business developments and outlook after market close on Thursday, February 15, 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s product momentum, potential, progress and launches, our expected performance advantages and benefits of using our products and services, customer usage and adoption of our products and our financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts

Investors: investors@10xgenomics.com

Media: media@10xgenomics.com

10x Genomics, Inc.

Consolidated Statement of Operations

(Unaudited)

(In thousands, except share and per share data)





Three Months Ended

December 31,



Year Ended

December 31,



2023



2022



2023



2022

Revenue (1)

$         183,979



$         156,232



$         618,727



$         516,409

Cost of revenue (2)

68,197



36,827



209,414



120,386

Gross profit

115,782



119,405



409,313



396,023

Operating expenses:















Research and development (2)

65,267



63,614



270,332



265,667

In-process research and development

19,578





60,980



Selling, general and administrative (2)

86,125



78,887



343,330



298,300

Total operating expenses

170,970



142,501



674,642



563,967

Loss from operations

(55,188)



(23,096)



(265,329)



(167,944)

Other income (expense):















Interest income

4,637



2,815



16,906



6,647

Interest expense

(8)



(125)



(33)



(476)

Other income (expense), net

3,961



3,995



(307)



(198)

Total other income

8,590



6,685



16,566



5,973

Loss before provision for income taxes

(46,598)



(16,411)



(248,763)



(161,971)

Provision for income taxes

2,354



804



6,336



4,029

Net loss

$          (48,952)



$          (17,215)



$       (255,099)



$       (166,000)

















Net loss per share, basic and diluted

$              (0.41)



$              (0.15)



$              (2.18)



$              (1.46)

Weighted-average shares used to compute net loss per share, basic and diluted

118,565,724



114,757,572



117,165,036



113,858,684

















(1)

The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company's Visium and Xenium products:

 





Three Months Ended

December 31,



Twelve Months Ended

December 31,





2023



2022



2023



2022

Instruments

















Chromium



$           11,150



$           15,243



$           47,866



$           58,552

Spatial



27,248



7,089



75,605



13,844

Total instruments revenue



38,398



22,332



123,471



72,396

Consumables

















Chromium



118,144



120,238



420,316



400,433

Spatial



22,170



11,359



59,237



35,155

Total consumables revenue



140,314



131,597



479,553



435,588

Services



5,267



2,303



15,703



8,425

Total revenue



$         183,979



$         156,232



$         618,727



$         516,409

 

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):





Three Months Ended

December 31,



Twelve Months Ended

December 31,





2023



2022



2023



2022

Americas

















United States



$           99,322



$           82,828



$         360,091



$         284,987

Americas (excluding United States)



4,520



2,794



13,101



8,791

Total Americas



103,842



85,622



373,192



293,778

Europe, Middle East and Africa



50,589



43,001



142,276



117,068

Asia-Pacific

















China¹



11,748



16,277



50,965



64,356

Asia-Pacific (excluding China)



17,800



11,332



52,294



41,207

Total Asia-Pacific



29,548



27,609



103,259



105,563

Total Revenue



$         183,979



$         156,232



$         618,727



$         516,409





1

Includes Hong Kong effective from the first quarter of 2023. Comparative periods have been adjusted for this inclusion.

 

(2) Includes stock-based compensation expense as follows:



Three Months Ended

December 31,



Year Ended

December 31,

(in thousands)

2023



2022



2023



2022

Cost of revenue

$           1,928



$           1,511



$           7,068



$           5,259

Research and development

17,608



17,865



72,804



59,211

Selling, general and administrative

19,382



21,598



87,078



72,378

Total stock-based compensation expense

$         38,918



$         40,974



$       166,950



$       136,848

 

10x Genomics, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)





December 31,



2023



2022

Assets







Current assets:







Cash and cash equivalents

$         359,284



$         219,746

Marketable securities

29,411



210,238

Restricted cash



2,633

Accounts receivable, net

114,832



104,211

Inventory

73,706



81,629

Prepaid expenses and other current assets

18,789



16,578

Total current assets

596,022



635,035

Property and equipment, net

279,571



289,328

Restricted cash



4,974

Operating lease right-of-use assets

65,361



69,882

Goodwill

4,511



4,511

Intangible assets, net

16,616



22,858

Other noncurrent assets

3,062



2,392

Total assets

$         965,143



$      1,028,980

Liabilities and stockholders' equity







Current liabilities:







Accounts payable

$           15,738



$           21,599

Accrued compensation and related benefits

30,105



32,675

Accrued expenses and other current liabilities

56,648



59,779

Deferred revenue

13,150



7,867

Operating lease liabilities

11,521



9,037

Total current liabilities

127,162



130,957

Operating lease liabilities, noncurrent

83,849



86,139

Deferred revenue, noncurrent

8,814



3,165

Other noncurrent liabilities

4,275



2,976

Total liabilities

224,100



223,237

Commitments and contingencies







Stockholders' equity:







Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or

outstanding as of December 31, 2023 and December 31, 2022



Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 119,095,362

and 115,195,009 shares issued and outstanding as of December 31, 2023 and 2022

2



2

Additional paid-in capital

2,025,890



1,839,397

Accumulated deficit

(1,284,420)



(1,029,321)

Accumulated other comprehensive loss

(429)



(4,335)

Total stockholders' equity

741,043



805,743

Total liabilities and stockholders' equity

$         965,143



$      1,028,980









 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-outlook-for-2024-302063485.html

SOURCE 10x Genomics, Inc

Get the next $TXG alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TXG

DatePrice TargetRatingAnalyst
2/13/2025$25.00 → $12.00Outperform → Market Perform
Leerink Partners
9/3/2024$35.00Outperform
Leerink Partners
7/22/2024$24.00Hold → Buy
Jefferies
7/18/2024$40.00 → $20.00Overweight → Neutral
JP Morgan
7/10/2024$55.00 → $25.00Buy → Hold
Deutsche Bank
6/27/2024Outperform → Peer Perform
Wolfe Research
6/25/2024Buy → Neutral
Guggenheim
6/3/2024$24.00Hold
Jefferies
More analyst ratings

$TXG
Press Releases

Fastest customizable press release news feed in the world

See more
  • 10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

    10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and infringed

    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • 10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

    New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology.

    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • 10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

    PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomic

    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$TXG
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TXG
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TXG
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TXG
SEC Filings

See more

$TXG
Leadership Updates

Live Leadership Updates

See more
  • 10x Genomics Announces Senior Leadership Changes

    PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

    $CPNG
    $GH
    $OZON
    $TXG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care
  • ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

    Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

    $RARE
    $TXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$TXG
Financials

Live finance-specific insights

See more
  • 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

    PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unpre

    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • 10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

    PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • 10x Genomics Reports Third Quarter 2024 Financial Results

    PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables.Began shipping GEM-X Flex, setting a new standard for the cost per cell for researchers and enabling the

    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$TXG
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more